Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMS Medical, which is engaged in the development and commercialization of therapeutic technologies, has reported a net income of C$0.3 million, or C$0.01 per share, for the fourth quarter ended December 31, 2008, compared to a net loss of C$11.7 million, or C$0.13 per share, for the same quarter of 2007.
Subscribe to our email newsletter
For the year ended December 31, 2008, revenues were C$52.6 million, compared to nil revenues for the year ended December 31, 2007. Net loss was C$0.5 million, or C$0.01 per share, compared to a net loss of C$47.2 million, or C$0.56 per share, for 2007.
Kevin Giese, president and CEO of BioMS Medical, said: “Dirucotide has demonstrated the ability to safely affect multiple sclerosis (MS) progression in previous studies and we look forward to the results of the Canadian/European trial in the second half of this year. Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive MS.”